<DOC>
	<DOCNO>NCT00790244</DOCNO>
	<brief_summary>SSG XX phase II trial high-risk soft tissue sarcoma ( STS ) extremities trunk wall . Prognostic factor ( histopathological marker ) use identify high-risk tumor . SSG XX evaluate chemo- radiotherapy give adjuvantly patient . In specified group patient also preoperatively give therapy study .</brief_summary>
	<brief_title>A Scandinavian Sarcoma Group Protocol Patients With High-risk Soft Tissue Sarcoma Extremities Trunk Wall</brief_title>
	<detailed_description>SSG XX , third adjuvant STS protocol SSG , phase II non-randomized trial patient high risk develop metastasis . SSG XX base previous SSG trial ( SSG XIII ) regard use prognostic marker identify high-risk tumor include similar chemo- radiotherapy treatment schedule compare SSG XIII , new protocol also include treatment arm preoperative chemo- radiotherapy patient obvious risk intralesional surgery initially . Patients : In new adjuvant protocol SSG adopt inclusion decision algorithm base follow criterion : 1.vascular invasion 2. presence least two risk factor : tumor size = &gt; 8 cm , necrosis infiltrative growth ( define microscopically pathologist . The system develop retrospectively evaluation 434 primary histologically high grade ( III-IV ) STS SSG registry , later validate series 175 patient patient high risk metastasis ( &gt; 40 % ) low risk ( &lt; 15 % ) separate ( Engellau J et al.Eur J Ca 2007 43 : 1927-34 ) . Inclusion criterion : age ≥ 18 &lt; 75 . Primary end point metastasis-free survival . Local recurrence toxicity also study . Treatment : Six cycle doxorubicin 60mg/m2 ifosfamide 6g/m2 give adjuvantly ( patient ≥ 70y : 50mg/m2 5g/m2 ) . Dependent surgical resection margin , 36Gy 45Gy ( 1,8Gy per fraction , two fraction daily ) give interpolated chemotherapy . Conclusion : SSG XX evaluate chemo-and radiotherapy give adjuvantly patient STS high risk metastasis ( arm A ) . In specified group patient also preoperatively give therapy study ( arm B ) . Other sarcoma center invite participate study .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>Group A : Histological highgrade malignancy soft tissue sarcoma extremity trunk wall . Patients fulfil highrisk criterion define ( see detailed description ) Group B : Patients histological highgrade malignancy soft tissue sarcoma extremity trunk wall surgery carry obvious risk intralesional margin Other inclusion criterion therapy group A group B Age ≥ 18 ≤ 75 WHO grade 01 Adequate cardiac function ( LVEF ≥ 50 % ) Normal GFR ( clearance ) Adequate haematologic liver function All histotypes except list The following histological type : Extraskeletal osteosarcoma chondrosarcoma , Ewing/PNET , rhabdomyosarcoma , Kaposi´s sarcoma , malignant mesenchymoma , clear cell sarcoma , alveolar soft part sarcoma , epithelioid sarcoma Radiation induce sarcoma No previous anthracycline treatment Less 5 year free another primary malignancy More 12 week elapse since primary surgery ( Group A ) More 4 week diagnostic biopsy start chemotherapy ( Group B )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>Soft-tissue sarcoma</keyword>
	<keyword>prognostic factor</keyword>
	<keyword>adjuvant</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>radiotherapy</keyword>
	<keyword>metastases-free survival</keyword>
	<keyword>toxicity</keyword>
	<keyword>High malignancy grade</keyword>
	<keyword>High-risk metastasis</keyword>
	<keyword>Adult</keyword>
</DOC>